Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

af Antonia, Scott J, Borghaei, Hossein, Ramalingam, Suresh S, Horn, Leora, De Castro Carpeño, Javier, Pluzanski, Adam, Burgio, Marco A, Garassino, Marina, Chow, Laura Q M, Gettinger, Scott, Crinò, Lucio, Planchard, David, Butts, Charles, Drilon, Alexander, Wojcik-Tomaszewska, Joanna, Otterson, Gregory A, Agrawal, Shruti, Li, Ang, Penrod, John R, Brahmer, Julie
Udgivet i Lancet Oncol (2019)

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

af Borghaei, Hossein, Gettinger, Scott, Vokes, Everett E., Chow, Laura Q. M., Burgio, Marco Angelo, de Castro Carpeno, Javier, Pluzanski, Adam, Arrieta, Oscar, Frontera, Osvaldo Arén, Chiari, Rita, Butts, Charles, Wójcik-Tomaszewska, Joanna, Coudert, Bruno, Garassino, Marina Chiara, Ready, Neal, Felip, Enriqueta, García, Miriam Alonso, Waterhouse, David, Domine, Manuel, Barlesi, Fabrice, Antonia, Scott, Wohlleber, Markus, Gerber, David E., Czyzewicz, Grzegorz, Spigel, David R., Crino, Lucio, Eberhardt, Wilfried Enst Erich, Li, Ang, Marimuthu, Sathiya, Brahmer, Julie
Udgivet i J Clin Oncol (2021)